Literature DB >> 10901161

Activation of c-jun N-terminal kinase by 4-1BB (CD137), a T cell co-stimulatory molecule.

H H Kim1, K Kwack, Z H Lee.   

Abstract

It has been widely accepted that T cell activation requires two signals; one from the binding of the antigen/major histocompatibility complex to the T-cell receptor (TCR)/CD3 complex and the other from the interaction between a surface molecule on antigen presenting cells and its receptor on T cells. The second signal is considered as co-stimulatory and the B7/CD28 pair has been well studied as a prototype. Recently 4-1BB (CD137) has been characterized as another co-stimulatory molecule for T cell activation. However, unlike the CD28/B7 pair, 4-1BB and its ligand 4-1BBL constitute a member of the tumor necrosis factor (TNF) receptor/TNF pair superfamily. The signaling mechanism of 4-1BB has not been revealed in detail. To investigate whether 4-1BB takes the signaling pathways analogous to those for TNF receptors, we generated polyclonal antibodies against human 4-1BB and 4-1BBL and established stable transfectants of the receptor and the ligand with a high level of cell surface expression. Over-expression of h4-1BB was found to result in the activation of c-Jun N-terminal kinase (JNK) in the human embryonic kidney cell line 293. In T cells, it has been previously demonstrated that JNK activation requires dual signals such as the ligation of TCR/CD3 complex plus CD28 co-stimulation or PMA plus ionomycin. The JNK activation by 4-1BB in Jurkat T cells was also found to require stimulation of the TCR/CD3 complex, consistent with the notion that 4-1BB functions as a co-stimulatory molecule for T cell activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901161

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  7 in total

1.  4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Cosette Dechant; Xiuyu Cui; Pakawat Chongsathidkiet; Daniel Wilkinson; Jessica Waibl-Polania; Luis Sanchez-Perez; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2019-12-23       Impact factor: 12.531

2.  FIP-fve Stimulates Cell Proliferation and Enhances IL-2 Release by Activating MAP2K3/p38α (MAPK14) Signaling Pathway in Jurkat E6-1 Cells.

Authors:  Kefei Gu; Tan Wang; Liying Peng; Yueliang Zhao
Journal:  Front Nutr       Date:  2022-05-09

3.  c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.

Authors:  Nathalie Arbour; Denise Naniche; Dirk Homann; Roger J Davis; Richard A Flavell; Michael B A Oldstone
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

Review 4.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

5.  Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-stimulatory Signal Domain Exhibits High Functional Potency.

Authors:  Jun-Ichi Nunoya; Michiaki Masuda; Chaobaihui Ye; Lishan Su
Journal:  Mol Ther Oncolytics       Date:  2019-03-23       Impact factor: 7.200

6.  Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor.

Authors:  Jiemiao Hu; Xueqing Xia; Richard Gorlick; Shulin Li
Journal:  Oncogene       Date:  2019-08-19       Impact factor: 9.867

7.  Activation of CD137 Signaling Enhances Vascular Calcification through c-Jun N-Terminal Kinase-Dependent Disruption of Autophagic Flux.

Authors:  Rui Chen; Yao Xu; Wei Zhong; Bo Li; Ping Yang; Zhong Qun Wang; Chen Shao; Cui Ping Wang; Jin Chuan Yan
Journal:  Mediators Inflamm       Date:  2018-09-26       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.